HPV vaccine is effective, safe 10 years after it's given

November 29, 2017
A decade of data on hundreds of boys and girls who received the HPV vaccine indicates the vaccine is safe and effective long term in protecting against the most virulent strains of the virus, researchers report. Credit: Phil Jones, Senior Photographer, Augusta University

A decade of data on hundreds of boys and girls who received the HPV vaccine indicates the vaccine is safe and effective long term in protecting against the most virulent strains of the virus, researchers report.

The findings support more widespread and early administration of the HPV vaccine before preadolescents and adolescents are exposed to the nation's most common sexually transmitted infection and the most common cause of cervical cancer, they report in the journal Pediatrics.

Some 79 million Americans, most in their late teens and early 20s, are infected with human papillomavirus, according to the Centers for Disease Control and Prevention. About half of those are infected with the most of the virus, which are targeted by the quadrivalent vaccine given to study participants.

"The vaccine was virtually 100 percent effective in preventing disease in these young individuals," says Dr. Daron G. Ferris, professor in the Department of Obstetrics and Gynecology at the Medical College of Georgia and at the Georgia Cancer Center at Augusta University.

The quadrivalent vaccine protects against HPV types 6, 11, 16 and 18. Types 16 and 18 account for essentially all cervical cancer and for most other HPV-related cancers like penile and anal cancers, according to the National Cancer Institute. Types 6 and 11 account for about 90 percent of genital warts as well as non-cancerous tumor growths in the respiratory tract.

No cases of disease related to these four HPV types were found in study participants, who received a three-dose regimen of the vaccine when they were ages 9-15 and sexually inactive, Ferris says.

Ferris, first author of the new study who led trials of the quadrivalent vaccine in 2002, says the earlier, shorter-term evaluation clearly indicated the vaccine worked.

"We also needed to look at long-term efficacy, safety and immunogenicity," he says. "We needed to answer questions like if we vaccinate earlier in life, will it last. The answer is yes, this prevention vaccine is working incredibly well 10 years later. A booster vaccine likely will not be needed by these young people. I think now we have come full circle."

The study was the longest follow up to date on the vaccine. Follow-up data on safety and efficacy has been assessed at up to six years in women age 15-26 and the current team of investigators also looked at data on the large cohort of young people two years ago.

Participants were followed at 34 sites in nine countries, including MCG and the Georgia Cancer Center in Augusta. Initially about one third of the 1,661 study participants received placebo, however the placebo group also received the vaccine 30 months into the study so those individuals were followed a shorter period of time, the researchers note.

While all participants remained disease free, the earlier vaccinations produced the most robust initial and long-term antibody response, Ferris says, of levels of the infection fighters that can be measured in the blood.

While about two-thirds of infected individuals can eventually clear the virus, it persists and can cause a wide range of health problems in the remainder, Ferris says. The vaccination is designed to better arm everyone's immune system to eliminate the virus.

The Food and Drug Administration approved the first quadrivalent vaccine, Gardasil, in June 2006. The vaccine is currently approved for patients ages 9-26.

Effectiveness assessments included looking for genital warts, precancerous and cancerous growths on the cervix and genitals as well as persistent HPV infections. Effectiveness evaluation began at 3.5 years and continued twice yearly during the 10-year-period.

Two-dose vaccines that cover nine HPV strains are rapidly replacing the three-dose quadrivalent vaccine, Ferris says.

"Now we need to push for more to get vaccinated," he says. "We are doing miserably in the United States."

About 43 percent of U.S. teens are up to date on recommended doses of the HPV vaccine, according to the CDC. The HPV can be given along with the meningococcal and tetanus, diphtheria and pertussis vaccines, to 11- and 12-year-olds, the researchers note.

Study participants reported sexual activity rates similar to other studies and numbers of new sexual partners were higher among males than females. Other sexually transmitted diseases, including gonorrhea and chlamydia, were found in a small percentage of over the years of follow up. Half of all sexually transmitted diseases occur in people age 15-24 and 1 in 4 sexually adolescent females have a like chlamydia or HPV, according to the CDC.

Explore further: New study finds improved vaccine that protects against nine types of HPV is highly effective

Related Stories

New study finds improved vaccine that protects against nine types of HPV is highly effective

September 6, 2017
Cervical cancer is the second most common cause of cancer-related death worldwide, with almost 300,000 deaths occurring each year. More than 80 percent of these deaths occur in developing nations. The advent of human papillomavirus ...

Vaccine to prevent most cervical cancers shows long-term effectiveness

September 6, 2017
A vaccine that can literally eradicate the majority of cervical cancer cases shows long-term effectiveness in a study published today in The Lancet. This study of 14,215 women in 18 countries extends and solidifies the initial ...

Experts say flu season could be severe this year

September 22, 2017
If last year's active flu season and this year's severe season in the Southern Hemisphere is any indication of what flu season will look like across the country beginning this fall, then it's important to get vaccinated soon ...

Two dose HPV vaccine effective in treating genital warts, study finds

May 15, 2017
As of this year, kids under the age of 15 only need 2 doses of HPV vaccine. New research out of Boston Medical Center, published online in the STD Journal, is the first published clinical evidence to support new recommendations ...

More U.S. teens getting vaccinated against HPV

August 24, 2017
(HealthDay)—Six out of 10 U.S. parents are choosing to get their children vaccinated against the cancer-causing human papillomavirus (HPV), which is spread by sexual contact, federal health officials reported Thursday.

Recommended for you

Higher blood sugar in early pregnancy raises baby's heart-defect risk

December 15, 2017
Higher blood sugar early in pregnancy raises the baby's risk of a congenital heart defect, even among mothers who do not have diabetes, according to a study led by researchers at the Stanford University School of Medicine.

Injuries from window blinds send two children to the emergency department every day

December 11, 2017
Most homes have them. They help keep our rooms warm or cold and even add a pop of color to tie the décor together. But window blinds can cause serious injuries or even death to young children. A new study from the Center ...

Blood flow altered in brains of preterm newborns vs. full-term infants

December 4, 2017
Cerebral blood flow (CBF) of key regions of newborns' brains is altered in very premature infants and may provide an early warning sign of disturbed brain maturation well before such injury is visible on conventional imaging, ...

HPV vaccine is effective, safe 10 years after it's given

November 29, 2017
A decade of data on hundreds of boys and girls who received the HPV vaccine indicates the vaccine is safe and effective long term in protecting against the most virulent strains of the virus, researchers report.

Antibiotics administered during labor delay healthy gut bacteria in babies

November 28, 2017
Antibiotics administered during labour for Group B Streptococcus (GBS) affect the development of gut bacteria in babies, according to a study from McMaster University.

Stress in pregnancy linked to changes in infant's nervous system, less smiling, less resilience

November 23, 2017
Maternal stress during the second trimester of pregnancy may influence the nervous system of the developing child, both before and after birth, and may have subtle effects on temperament, resulting in less smiling and engagement, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.